What is the risk of dehydration on GLP-1 medications?

Dehydration is a significant risk with GLP-1 therapy due to reduced thirst, nausea, vomiting, and diarrhea that can occur, especially during dose titration. Dehydration can lead to kidney problems, dizziness, fainting, and electrolyte imbalances. Warning signs include: dark yellow urine, infrequent urination, dizziness or lightheadedness, dry mouth, extreme thirst, fatigue, confusion, and rapid heartbeat. Prevent dehydration by: drinking at least 8-10 glasses of water daily, more if exercising or in hot weather; monitoring urine color (pale yellow is ideal); setting reminders to drink if appetite suppression reduces thirst signals; including hydrating foods like fruits and vegetables; limiting caffeine and alcohol; and seeking shade and rest in hot weather. If you experience vomiting or diarrhea, increase fluid intake and consider oral rehydration solutions with electrolytes. Severe dehydration requires medical attention - IV fluids may be necessary. SeraVia Hydration+ Restore provides electrolytes formulated for GLP-1 users who may struggle with hydration.